MedPath

Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study Participants

Completed
Conditions
HIV Infections
Interventions
Drug: Delayed ART
Drug: Continuous ART
Registration Number
NCT00386035
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to compare the effects of two different anti-HIV drug regimens on HIV transmission risk behavior among SMART study participants.

Detailed Description

It is important to consider the role that HIV infected individuals play in ongoing HIV transmission. Different anti-HIV treatment regimens may lead to variations in HIV transmission risk behavior among HIV infected individuals. HIV infected people with viral loads of less than 1,000 copies/ml are less likely to transmit HIV through heterosexual sex. However, condom use sometimes decreases after individuals start combination antiretroviral therapy (ART); also, some studies have shown an increased rate in acquiring sexually transmitted infections (STIs) following initiation of ART, and those on ART may transmit a drug-resistant strain of HIV. In the SMART study, participants were randomly assigned to one of two treatment groups:

* Group 1 participants will follow a drug conservation (DC) regimen in which ART will be stopped or deferred until CD4 cell count drops below 250 cells/mm3, will be initiated until CD4 cell count is at least 350 cells/mm3, and then will be followed by episodic ART based on CD4 cell count.

* Group 2 participants will follow a viral suppression (VS) regimen in which ART is continued to keep viral loads as low as possible, regardless of CD4 cell count.

The purpose of this study is to compare how the DC and VS regimens affect HIV transmission risk behavior among SMART study participants.

At baseline, participants will complete a questionnaire about their sexual behavior during the previous 2 months. They will also undergo urine and blood collection for STI testing. These same procedures will occur at Months 4 and 12, then every year thereafter for the first 4 years that a participant is in the parent study. Participants and their physicians will be notified of STI testing results so that patients can be referred to appropriate care.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
883
Inclusion Criteria
  • Coenrollment in the SMART study
  • Parent or guardian willing to provide informed consent, if applicable
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
1: DC GroupDelayed ARTHIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3. Participants are followed by episodic ART based on CD4 cell count.
2: VS GroupContinuous ARTHIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
Primary Outcome Measures
NameTimeMethod
To compare the DC group to the VS group for HIV transmission and risk behaviorsAt the end of study
Secondary Outcome Measures
NameTimeMethod
To compare the DC and VS groups for HIV transmission risk behavior in subgroups defined by age, gender, possible transmission category, HIV RNA level, and baseline genotypic resistance pattern.At the end of study
To evaluate the correlation between self-reported transmission risk behavior and the acquisition of certain sexually transmitted diseases as specified in the protocol.At the end of study
To develop analytic techniques to combine behavioral and biological data into a measure of overall transmission riskAt the end of study
To evaluate the correlation between self-reported adherence to ART and HIV transmission risk behavior for participants on ARTAt the end of study
To compare the effects of continuing ART in the VS group to stopping ART in the DC group on HIV transmission risk behavior among participants who are on ART at enrollmentAt the end of study
To compare the VS group to the DC group on HIV transmission risk behavior in participants who are not on ART at enrollmentAt the end of study

Trial Locations

Locations (58)

UCSF PHP, Gen. Internal Medicine Practice CRS

🇺🇸

San Francisco, California, United States

Miami VAMC CRS

🇺🇸

Miami, Florida, United States

Dr. Shawn Hassler Med. Practice CRS

🇺🇸

San Francisco, California, United States

Dr. William Owen Med. Practice CRS

🇺🇸

San Francisco, California, United States

Castro-Mission Health Ctr. CRS

🇺🇸

San Francisco, California, United States

Philadelphia FIGHT - Dr. Jay Kostman CRS

🇺🇸

Philadelphia, Pennsylvania, United States

Temple Univ. School of Medicine CRS

🇺🇸

Philadelphia, Pennsylvania, United States

Harper Hosp., Detroit CRS

🇺🇸

Detroit, Michigan, United States

Dr. Robert Scott Med. Practice CRS

🇺🇸

Oakland, California, United States

Dr. M. Estes Med. Practice CRS

🇺🇸

Mill Valley, California, United States

UCSF, Fresno, School of Medicine, Dept. of Internal Medicine CRS

🇺🇸

Fresno, California, United States

Dr. Virginia Cafaro Med. Practice CRS

🇺🇸

San Francisco, California, United States

San Francisco VAMC, Infectious Diseases Clinic CRS

🇺🇸

San Francisco, California, United States

Positive Health Program Clinic (San Francisco Gen. Hosp.) CRS

🇺🇸

San Francisco, California, United States

Western Infectious Disease Consultants CRS

🇺🇸

Wheat Ridge, Colorado, United States

Bronx-Lebanon Hosp. Ctr. CRS

🇺🇸

Bronx, New York, United States

Detroit Community Health Connection, Inc. CRS

🇺🇸

Detroit, Michigan, United States

Montefiore Med. Ctr., AIDS Ctr. CRS

🇺🇸

Bronx, New York, United States

PeaceHealth Med. Group - Hilyard Street Clinic CRS

🇺🇸

Eugene, Oregon, United States

Albert Einstein Med. Ctr., Immunodeficiency Ctr. CRS

🇺🇸

Philadelphia, Pennsylvania, United States

MediCorp, Infectious Disease Associates CRS

🇺🇸

Fredericksburg, Virginia, United States

Denver Infectious Diseases Consultants CRS

🇺🇸

Denver, Colorado, United States

Eastside Family Health Ctr. CRS

🇺🇸

Denver, Colorado, United States

Legacy Clinic Good Samaritan CRS

🇺🇸

Portland, Oregon, United States

Kaiser Permanente of Denver CRS

🇺🇸

Denver, Colorado, United States

Univ. of Colorado Health Science Ctr. CRS

🇺🇸

Denver, Colorado, United States

Denver Public Health CRS - INSIGHT

🇺🇸

Denver, Colorado, United States

Denver Public Health CRS

🇺🇸

Denver, Colorado, United States

Multnomah County Health Dept., HIV Health Services Ctr. CRS

🇺🇸

Portland, Oregon, United States

Denver VAMC CRS

🇺🇸

Denver, Colorado, United States

The Research & Education Group-Portland CRS

🇺🇸

Portland, Oregon, United States

Kaiser Immune Deficiency Clinic of Portland CRS

🇺🇸

Portland, Oregon, United States

Legacy Clinic Emanuel CRS

🇺🇸

Portland, Oregon, United States

Oregon Health & Sciences Univ. Internal Medicine (L-475) CRS

🇺🇸

Portland, Oregon, United States

Hanover Med. Park (Mechanicsville, VA) CRS

🇺🇸

Mechanicsville, Virginia, United States

Eastern Virginia Med. School, Ctr. for the Comprehensive Care of Immune Deficiency CRS

🇺🇸

Norfolk, Virginia, United States

Petersburg Health Care Alliance CRS

🇺🇸

Petersburg, Virginia, United States

East Bay AIDS Ctr. CRS

🇺🇸

Oakland, California, United States

Beacon Clinic at Boulder CRS

🇺🇸

Boulder, Colorado, United States

Washington DC VAMC, Washington Regional AIDS Program, Infectious Diseases CRS

🇺🇸

Washington, District of Columbia, United States

Cooper Hospital/Univ. Med. Ctr., The Cooper Early Intervention Program (EIP) CRS

🇺🇸

Camden, New Jersey, United States

Atlanta VAMC CRS

🇺🇸

Decatur, Georgia, United States

McAuley Health Ctr. CRS

🇺🇸

Grand Rapids, Michigan, United States

New Jersey Medical School- Adult Clinical Research Ctr. CRS

🇺🇸

Newark, New Jersey, United States

South Jersey Infectious Disease, Cape Clinical Trials CRS

🇺🇸

Somers Point, New Jersey, United States

St. Vincent Hosp. & Med. Ctr. CRS

🇺🇸

New York, New York, United States

Bronx Prevention Center CRS

🇺🇸

Bronx, New York, United States

Wayne State Univ. CRS

🇺🇸

Detroit, Michigan, United States

Wayne State Univ. INSIGHT CRS

🇺🇸

Detroit, Michigan, United States

Providence Portland Med. Ctr., Ambulatory Care and Education Ctr. CRS

🇺🇸

Portland, Oregon, United States

Cooper Univ. Hosp. CRS

🇺🇸

Camden, New Jersey, United States

The Early Intervention Program at Kennedy Hosp. CRS

🇺🇸

Voorhees, New Jersey, United States

Vernon Harris East End Community Health Ctr. CRS

🇺🇸

Richmond, Virginia, United States

CrossOver Health Ctr. CRS

🇺🇸

Richmond, Virginia, United States

South Richmond Health Care Ctr. CRS

🇺🇸

Richmond, Virginia, United States

Hunter Holmes McGuire VAMC CRS

🇺🇸

Richmond, Virginia, United States

VCU Health Systems, Infectious Disease Clinic CRS

🇺🇸

Richmond, Virginia, United States

AIDS Healthcare Foundation CRS

🇺🇸

Beverly Hills, California, United States

© Copyright 2025. All Rights Reserved by MedPath